By Associate Professor Meg Jardine

Journal articles

O’Hara DV; Neuen BL; Jardine MJ, 2020, 'Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE', Journal of Nephrology, 33, pp. 977 - 983, http://dx.doi.org/10.1007/s40620-020-00809-x

Smyth B; Zuo L; Gray NA; Chan CT; de Zoysa JR; Hong D; Rogers K; Wang J; Cass A; Gallagher M; Perkovic V; Jardine M, 2020, 'No evidence of a legacy effect on survival following randomization to extended hours dialysis in the ACTIVE Dialysis trial', Nephrology, 25, pp. 792 - 800, http://dx.doi.org/10.1111/nep.13737

Zhu B; Jun M; Jardine MJ; Wang YJ; Perkovic V, 2020, 'Haemodialysis duration, frequency and intensity for end-stage kidney disease', Cochrane Database of Systematic Reviews, 2020, http://dx.doi.org/10.1002/14651858.CD010064.pub2

Clase CM; Fu EL; Joseph M; Beale RCL; Dolovich MB; Jardine M; Mann JFE; Pecoits-Filho R; Winkelmayer WC; Carrero JJ, 2020, 'Cloth masks may prevent transmission of COVID-19: An evidence-based, risk-based approach', Annals of Internal Medicine, 173, pp. 489 - 492, http://dx.doi.org/10.7326/M20-2567

Shaman AM; Smyth B; Arnott C; Palmer SC; Mihailidou AS; Jardine MJ; Gallagher MP; Perkovic V; Jun M, 2020, 'Comparative efficacy and safety of bp-lowering pharmacotherapy in patients undergoing maintenance dialysis: A network meta-analysis of randomized, controlled trials', Clinical Journal of the American Society of Nephrology, 15, pp. 1129 - 1138, http://dx.doi.org/10.2215/CJN.12201019

Krishnasamy R; Hawley CM; Jardine MJ; Roberts MA; Cho Y; Wong M; Heath A; Nelson CL; Sen S; Mount PF; Pascoe EM; Vergara LA; Paul-Brent PA; Toussaint ND; Johnson DW; Hutchison CA, 2020, 'A trial evaluating mid cut-off value membrane clearance of albumin and light chains in hemodialysis patients: A safety device study', Blood Purification, 49, pp. 468 - 478, http://dx.doi.org/10.1159/000505567

LI J; JARDINE MJ; NEAL B; HEERSPINK HL; CANNON C; AGARWAL R; BAKRIS G; CHARYTAN DM; ZEEUW DD; EDWARDS R; GREENE TOM; LEVIN A; POLLOCK CA; ROSENTHAL N; WHEELER DC; ZHANG H; ZINMAN B; PERKOVIC V; MAHAFFEY KW; ARNOTT C, 2020, '27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease', Diabetes, 69, http://dx.doi.org/10.2337/db20-27-or

Kang A; Neuen B; Heerspink HL; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris G; Charytan DM; De Zeeuw D; Greene T; Levin A; Pollock C; Wheeler D; Zinman B; Mahaffey KW; Perkovic V; Jardine M; Lambers Heerspink H, 2020, 'P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', Nephrology Dialysis Transplantation, 35, pp. gfaa142.p1013, http://dx.doi.org/10.1093/ndt/gfaa142.p1013

Kang A; Smyth B; Neuen B; Lambers Heerspink H; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris G; Charytan DM; De Zeeuw D; Greene T; Levin A; Pollock C; Wheeler D; Zinman B; Mahaffey KW; Perkovic V; Jardine M, 2020, 'P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa142.p1019

Young T; Li J-W; Kang A; Heerspink H; Hockham C; Arnott C; Neuen B; Zoungas S; Mahaffey KW; Perkovic V; De Zeeuw D; Fulcher G; Neal B; Jardine M, 2020, 'P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM', Nephrology Dialysis Transplantation, 35, pp. gfaa142.p1028, http://dx.doi.org/10.1093/ndt/gfaa142.p1028

Smyth B; Chan CT; Grieve SM; Puranik R; Zuo L; Hong D; Gray NA; De Zoysa JR; Scaria A; Gallagher M; Perkovic V; Jardine M, 2020, 'Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis', Journal of Cardiac Failure, 26, pp. 482 - 491, http://dx.doi.org/10.1016/j.cardfail.2020.03.010

Arnott C; Huang Y; Neuen BL; Di Tanna GL; Cannon CP; Oh R; Edwards R; Kavalam M; Rosenthal N; Perkovic V; Jardine MJ; Mahaffey K; Neal B, 2020, 'The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.', Diabetes Obes Metab, 22, pp. 1753 - 1766, http://dx.doi.org/10.1111/dom.14091

Sriravindrarajah A; Kotwal SS; Sen S; McDonald S; Jardine M; Cass A; Gallagher M, 2020, 'Impact of supplemental private health insurance on dialysis and outcomes', Internal Medicine Journal, 50, pp. 542 - 549, http://dx.doi.org/10.1111/imj.14375

Sukkar L; Kang A; Hockham C; Young T; Jun M; Foote C; Pecoits-Filho R; Neuen B; Rogers K; Pollock C; Cass A; Sullivan D; Wong G; Knight J; Peiris D; Gallagher M; Jardine M, 2020, 'Incidence and associations of chronic kidney disease in community participants with diabetes: A 5-year prospective analysis of the EXTEND45 study', Diabetes Care, 43, pp. 982 - 990, http://dx.doi.org/10.2337/dc19-1803

Jardine MJ; Zhou Z; Mahaffey KW; Oshima M; Agarwal R; Bakris G; Bajaj HS; Bull S; Cannon CP; Charytan DM; De Zeeuw D; Di Tanna GL; Greene T; Heerspink HJL; Levin A; Neal B; Pollock C; Qiu R; Sun T; Wheeler DC; Zhang H; Zinman B; Rosenthal N; Perkovic V, 2020, 'Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: A secondary analysis of the CREDENCE randomized trial', Journal of the American Society of Nephrology, 31, pp. 1128 - 1139, http://dx.doi.org/10.1681/ASN.2019111168

Foote C; Hockham C; Sukkar L; Campain A; Kang A; Young T; Cass A; Chow CK; Comino E; Gallagher M; Jan S; Knight J; Liu B; McNamara M; Peiris D; Pollock C; Sullivan D; Wong G; Zoungas S; Rogers K; Jun M; Jardine M; Harris M, 2020, 'Examining outcomes in chronic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study', JMIR Research Protocols, 9, pp. e15646, http://dx.doi.org/10.2196/15646

Rhee JJ; Jardine MJ; Chertow GM; Mahaffey KW, 2020, 'Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY', Diabetes, Obesity and Metabolism, 22, pp. 46 - 54, http://dx.doi.org/10.1111/dom.13987

Foote C; Hockham C; Sukkar L; Campain A; Kang A; Young T; Cass A; Chow CK; Comino E; Gallagher M; Jan S; Knight J; Liu B; McNamara M; Peiris D; Pollock C; Sullivan D; Wong G; Zoungas S; Rogers K; Jun M; Jardine M, 2020, 'Examining outcomes in chronic disease in the 45 and up study (the EXTEnD45 study): Protocol for an Australian linked cohort study', JMIR Research Protocols, 9, pp. e15646, http://dx.doi.org/10.2196/15646

Cannon CP; Perkovic V; Agarwal R; Baldassarre J; Bakris G; Charytan DM; De Zeeuw D; Edwards R; Greene T; Heerspink HJL; Jardine MJ; Levin A; Li JW; Neal B; Pollock C; Wheeler DC; Zhang H; Zinman B; Mahaffey KW, 2020, 'Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial', Circulation, 141, pp. 407 - 410, http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044359

Arnott C; Li Q; Kang A; Neuen BL; Bompoint S; Lam CSP; Rodgers A; Mahaffey KW; Cannon CP; Perkovic V; Jardine MJ; Neal B, 2020, 'Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis', Journal of the American Heart Association, 9, pp. e014908, http://dx.doi.org/10.1161/JAHA.119.014908

Heerspink HJL; Oshima M; Jardine MJ; Agarwal R; Bakris GL; Cannon CP; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; Neal B; Pollock CA; Rosenthal N; Wheeler DC; Zhang H; Zinman B; Perkovic V, 2020, 'Acute Declines in eGFR During Treatment with Canagliflozin (CANA) and Its Implications for Clinical Practice: Insights from CREDENCE', Journal of the American Society of Nephrology, 31, pp. 342 - 343, http://dx.doi.org/10.1681/asn.20203110s1342b

Neuen BL; Yu J; Li Q; Perkovic V; Arnott CG; Neal B; Heerspink HJL; Agarwal R; Bakris GL; Cannon CP; de Zeeuw D; Charytan DM; Levin A; Di Tanna GL; Matthews DR; Pollock CA; Wheeler DC; Mahaffey KW; Jardine MJ, 2020, 'Canagliflozin Across the Spectrum of Kidney Function and Albuminuria: Integrated Data from CANVAS and CREDENCE', Journal of the American Society of Nephrology, 31, pp. b6 - b6, http://dx.doi.org/10.1681/asn.20203110s1b6a

Kang A; Neuen BL; Heerspink HJL; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris GL; Charytan DM; de Zeeuw D; Greene T; Levin A; Pollock CA; Wheeler DC; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ, 2020, 'Canagliflozin and Risk of Genital Infections and Urinary Tract Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial', Journal of the American Society of Nephrology, 31, pp. 343 - 343, http://dx.doi.org/10.1681/asn.20203110s1343c

Kang A; Smyth B; Neuen BL; Heerspink HJL; Di Tanna GL; Neal B; Zhang H; Hockham C; Agarwal R; Bakris GL; Charytan DM; de Zeeuw D; Greene T; Levin A; Pollock CA; Wheeler DC; Zinman B; Mahaffey KW; Perkovic V; Jardine MJ, 2020, 'Canagliflozin and Risk of Skin and Soft Tissue Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial', Journal of the American Society of Nephrology, 31, pp. 344 - 344, http://dx.doi.org/10.1681/asn.20203110s1344a

Oshima M; Neuen BL; Li J; Perkovic V; Charytan DM; de Zeeuw D; Edwards R; Greene T; Levin A; Mahaffey KW; De Nicola L; Pollock CA; Rosenthal N; Wheeler DC; Jardine MJ; Heerspink HJL, 2020, 'Early Change in Albuminuria with Canagliflozin (CANA) Predicts Kidney and Cardiovascular (CV) Outcomes', Journal of the American Society of Nephrology, 31, pp. 344 - 344, http://dx.doi.org/10.1681/asn.20203110s1344b

Levin A; Neuen BL; Mahaffey KW; Cannon CP; Jardine MJ; Heerspink HJL; Neal B; Arnott CG; Zhou Z; Charytan DM; Agarwal R; Bakris GL; de Zeeuw D; Greene T; Wheeler DC; Rosenthal N; Zhang H; Zinman B; Perkovic V; Pollock CA, 2020, 'Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes by Baseline Loop Diuretic Use: Data from the CREDENCE Trial', Journal of the American Society of Nephrology, 31, pp. 342 - 342, http://dx.doi.org/10.1681/asn.20203110s1342a

Young TK; Li J; Kang A; Heerspink HJL; Hockham C; Arnott CG; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine MJ, 2020, 'Effects of Canagliflozin on Major Adverse Cardiovascular Events in Patients with Different Baseline Levels of Type 2 Diabetes Disease Severity: Results from the CANVAS Program', Journal of the American Society of Nephrology, 31, pp. 344 - 344, http://dx.doi.org/10.1681/asn.20203110s1344c

Bakris GL; Jardine MJ; Zhou Z; Heerspink HJL; Li Q; Agarwal R; Charytan DM; Oh R; Pollock CA; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V, 2020, 'Renal, Cardiovascular (CV), and Safety Outcomes of Canagliflozin (CANA) According to Baseline Albuminuria: A CREDENCE Secondary Analysis', Journal of the American Society of Nephrology, 31, pp. 328 - 328, http://dx.doi.org/10.1681/asn.20203110s1328a

Jardine M; Zhou Z; Heerspink HJL; Li Q; Agarwal R; Bakris G; Charytan DM; Oh R; Pollock C; Wheeler DC; Zeeuw DD; Zhang H; Zinman B; Mahaffey KW; Perkovic V, 2020, 'SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS', Kidney International Reports, 5, pp. S67 - S67, http://dx.doi.org/10.1016/j.ekir.2020.02.166

Hockham C; Bao L; Tiku A; Badve S; Gallagher MP; Jardine MJ; Jha V; Woodward M; Jun M, 2020, 'Sex Differences in CKD Prevalence in Asia: A Systematic Review and Meta-Analysis', Journal of the American Society of Nephrology, 31, pp. 179 - 179, http://dx.doi.org/10.1681/asn.20203110s1179c

OSHIMA M; Wong MG; Hara A; Toyama T; Jun M; Jardine M; Pollock C; Woodward M; Chalmers J; Perkovic V; Wada T, 2020, 'SUN-161 CIRCULATING AUTOANTIBODIES TO ERYTHROPOIETIN RECEPTOR AND KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES MELLITUS: RESULTS FROM THE ADVANCE STUDIES', Kidney International Reports, 5, pp. S267 - S267, http://dx.doi.org/10.1016/j.ekir.2020.02.690

Arnott C; Li J-W; Cannon CP; Neuen B; Heerspink HL; Neal B; Charytan DM; Agarwal R; Bakris GL; De Zeeuw D; Greene T; Levin A; Pollock C; Chang T; Rosenthal N; Zhang H; Zinman B; Perkovic V; Jardine M; Mahaffey K, 2020, 'THE EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE AND CARDIOVASCULAR DEATH BY BASELINE PARTICIPANT CHARACTERISTICS: ANALYSIS OF THE CREDENCE TRIAL', Journal of the American College of Cardiology, 75, pp. 674, http://dx.doi.org/10.1016/s0735-1097(20)31301-2

Smyth B; van den Broek-Best O; Hong D; Howard K; Rogers K; Zuo L; Gray NA; de Zoysa JR; Chan CT; Lin H; Zhang L; Xu J; Cass A; Gallagher M; Perkovic V; Jardine M, 2019, 'Varying association of extended hours dialysis with quality of life', Clinical Journal of the American Society of Nephrology, 14, pp. 1751 - 1762, http://dx.doi.org/10.2215/CJN.06800619

Goldstein CE; Weijer C; Taljaard M; Al-Jaishi AA; Basile E; Brehaut J; Cook CL; Grimshaw JM; Lacson E; Lindsay C; Jardine M; Dember LM; Garg AX, 2019, 'Ethical Issues in Pragmatic Cluster-Randomized Trials in Dialysis Facilities', American Journal of Kidney Diseases, 74, pp. 659 - 666, http://dx.doi.org/10.1053/j.ajkd.2019.04.019

Smyth B; Trongtrakul K; Haber A; Talbot B; Hawley C; Perkovic V; Woodward M; Jardine M, 2019, 'Inequities in the global representation of sites participating in large, multicentre dialysis trials: A systematic review', BMJ Global Health, 4, pp. e001940, http://dx.doi.org/10.1136/bmjgh-2019-001940

Neuen BL; Young T; Heerspink HJL; Neal B; Perkovic V; Billot L; Mahaffey KW; Charytan DM; Wheeler DC; Arnott C; Bompoint S; Levin A; Jardine MJ, 2019, 'SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis', The Lancet Diabetes and Endocrinology, 7, pp. 845 - 854, http://dx.doi.org/10.1016/S2213-8587(19)30256-6

Neuen BL; Cherney DZ; Jardine MJ; Perkovic V, 2019, 'Sodium-glucose cotransporter inhibitors in type 2 diabetes: Thinking beyond glucose lowering', CMAJ, 191, pp. E1128 - E1135, http://dx.doi.org/10.1503/cmaj.190047

Sarnak MJ; Amann K; Bangalore S; Cavalcante JL; Charytan DM; Craig JC; Gill JS; Hlatky MA; Jardine AG; Landmesser U; Newby LK; Herzog CA; Cheung M; Wheeler DC; Winkelmayer WC; Marwick TH; Banerjee D; Briguori C; Chang TI; Chen CL; deFilippi CR; Ding X; Ferro CJ; Gill J; Gössl M; Isbel NM; Ishii H; Jardine MJ; Kalra PA; Laufer G; Lentine KL; Lobdell K; Lok CE; London GM; Małyszko J; Mark PB; Marwan M; Nie Y; Parfrey PS; Pecoits-Filho R; Pilmore H; Qunibi WY; Raggi P; Rattazzi M; Rossignol P; Ruturi J; Sabanayagam C; Shanahan CM; Shroff GR; Shroff R; Webster AC; Weiner DE; Winther S; Wiseman AC; Yip A; Zarbock A, 2019, 'Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review', Journal of the American College of Cardiology, 74, pp. 1823 - 1838, http://dx.doi.org/10.1016/j.jacc.2019.08.1017

Zhou Z; Jardine M; Perkovic V; Matthews DR; Mahaffey KW; de Zeeuw D; Fulcher G; Desai M; Oh R; Simpson R; Watts NB; Neal B, 2019, 'Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program', Diabetologia, 62, pp. 1854 - 1867, http://dx.doi.org/10.1007/s00125-019-4955-5

Gray NA; Zuo L; Hong D; Smyth B; Jun M; De Zoysa J; Vo K; Howard K; Wang J; Lu C; Liu Z; Cass A; Perkovic V; Jardine M, 2019, 'Quality of life in caregivers compared with dialysis recipients: The Co-ACTIVE sub-study of the ACTIVE dialysis trial', Nephrology, 24, pp. 1056 - 1063, http://dx.doi.org/10.1111/nep.13530

Smyth B; Haber A; Trongtrakul K; Hawley C; Perkovic V; Woodward M; Jardine M, 2019, 'Representativeness of Randomized Clinical Trial Cohorts in End-stage Kidney Disease: A Meta-analysis', JAMA Internal Medicine, 179, pp. 1316 - 1324, http://dx.doi.org/10.1001/jamainternmed.2019.1501

Jardine MJ; Mahaffey KW; Perkovic V, 2019, 'Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply', The New England journal of medicine, 381, pp. 1089 - 1090, http://dx.doi.org/10.1056/NEJMc1909687

Mahaffey KW; Jardine MJ; Bompoint S; Cannon CP; Neal B; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Capuano G; De Zeeuw D; Greene T; Levin A; Pollock C; Sun T; Wheeler DC; Yavin Y; Zhang H; Zinman B; Rosenthal N; Brenner BM; Perkovic V, 2019, 'Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial', Circulation, 140, pp. 739 - 750, http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042007

Wyld MLR; Morton RL; Clayton P; Wong MG; Jardine M; Polkinghorne K; Chadban S, 2019, 'The impact of progressive chronic kidney disease on health-related quality-of-life: a 12-year community cohort study', Quality of Life Research, 28, pp. 2081 - 2090, http://dx.doi.org/10.1007/s11136-019-02173-1

Ha JT; Neuen BL; Cheng LP; Jun M; Toyama T; Gallagher MP; Jardine MJ; Sood MM; Garg AX; Palmer SC; Mark PB; Wheeler DC; Jha V; Freedman B; Johnson DW; Perkovic V; Badve SV, 2019, 'Benefits and harms of oral anticoagulant therapy in chronic kidney disease', Annals of Internal Medicine, 171, pp. 181 - 189, http://dx.doi.org/10.7326/M19-0087

Zhan Z; Smyth B; Toussaint ND; Gray NA; Zuo L; De Zoysa JR; Chan CT; Jin C; Scaria A; Hawley CM; Perkovic V; Jardine MJ; Zhang L, 2019, 'Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study', BMC Nephrology, 20, pp. 258, http://dx.doi.org/10.1186/s12882-019-1438-3

Graham-Brown MPM; Jardine MJ; Burton JO, 2019, 'Cardiovascular adaptations associated with exercise in patients on hemodialysis', Seminars in Dialysis, 32, pp. 361 - 367, http://dx.doi.org/10.1111/sdi.12789

Jardine MJ; Li N; Ninomiya T; Feng X; Zhang J; Shi J; Zhang Y; Zhang R; Zhang J; Hao J; Perkovic V; Heerspink HL; Wu Y; Yan LL; Neal B, 2019, 'Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial', Journal of Renal Nutrition, 29, pp. 276 - 284, http://dx.doi.org/10.1053/j.jrn.2018.10.009

Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; De Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW; Jha V, 2019, 'Canagliflozin and renal outcomes in type 2 diabetes and nephropathy', New England Journal of Medicine, 380, pp. 2295 - 2306, http://dx.doi.org/10.1056/NEJMoa1811744

Wong MG; Ninomiya T; Liyanage T; Sukkar L; Hirakawa Y; Wang Y; Wyld MLR; Morton RL; Chadban S; Howard K; Jardine MJ, 2019, 'Physical component quality of life reflects the impact of time and moderate chronic kidney disease, unlike SF-6D utility and mental component SF-36 quality of life: An AusDiab analysis', Nephrology, 24, pp. 605 - 614, http://dx.doi.org/10.1111/nep.13445

Back to profile page